Introduction
With better understanding of cancer genetics and availability of advanced sequencing technologies, cancer risk prediction may become accurate and reliable in the near future. This creates a high demand for safe and effective cancer prevention agents. In addition new diagnostic tools are capable of detecting cancer at early stages when use of standard chemotherapy is questionable due to its harmful effects on normal tissues. We have recently discovered a new class of anti-cancer small molecules with novel mechanisms of activity, named Curaxins (1) . Curaxins simultaneously modulate several signaling pathways that are commonly involved in transformation as well as other stages of cancer (e.g., the p53, NF-κB, and HSF1 pathways); this results in tumor-specific cytotoxicity (1, 2) . These pathways are involved in transformation as well as other stages of cancer and their modulation may influence tumor appearance and progression in tumor prone individuals.
The anti-cancer effects of Curaxins on the p53, NF-κB and HSF1 pathways in tumor cells are due to suppression of activity of the Facilitates Chromatin Transcription (FACT) complex (1) . FACT is a heterodimeric complex of two subunits, Structure Specific Recognition Protein 1 (SSRP1) and Suppressor of Ty 16 (SPT16), which is involved in transcription of genes with highly ordered chromatin structure through its bidirectional nucleosome remodeling activity (destabilizing nucleosomes to allow passage of RNA polymerases and stabilizing nucleosomes afterwards) (for review see (3) ). FACT is also involved in replication and mitosis (4), (5) . We found that FACT is overexpressed in many types of tumor cells and in mammary tumors in mice and that survival of tumor cells depends on FACT levels (1) . We also showed that FACT is required for NF-κB-dependent transcription (1) . Curaxins impact FACT function by altering chromatin structure such that FACT becomes tightly bound (or "trapped") in chromatin.
This depletes the pool of soluble active FACT in the nucleoplasm and thereby inhibits NF-κB-(and presumably HSF1 (6)) dependent transcription (1) .
Chromatin-trapping of FACT by Curaxins also leads to casein kinase 2 (CK2)-dependent phosphorylation and activation of p53 (1) . Therefore, Curaxins alter the activity of FACT, suppress transcription of NF-κB-and HSF1-dependent genes, and activate p53 -all properties which compromise tumor cell survival.
Based upon these findings, we hypothesized that FACT might be involved in tumor transformation and that Curaxins, therefore, might suppress tumor formation by modulating FACT activity in precancerous cells. To test this hypothesis, we used the MMTV-neu transgenic mouse model of mammary carcinogenesis, in which mammary tumor formation is induced through ectopic expression of the Her2/neu proto-oncogene driven by the steroid receptorresponsive promoter from the long terminal repeats of Mouse Mammary Tumor Virus (MMTV) (7) . Transgene expression in these mice is limited to tissues that express steroid receptors in female, such as mammary epithelial cells and ovary.
Mammary tumors in these animals recapitulate histopathological features of human breast adenocarcinomas (8) . A role for p53 suppression and NF-κB activation in promoting tumor formation in the MMTV-neu model was previously demonstrated (9) (10) (11) (12) . Inflammation, which is always associated with increased hydroxyethyl)piperazine-N'-ethanesulfonic acid (HEPES), bovine serum albumin (BSA), cholera toxin and Trizol were purchased from Invitrogen, Inc.
Cells
All human breast cancer cells were obtained from ATCC. Cells were frozen after 2 passages and used after thawing for no longer than 10-20 passages. Primary human mammary epithelial cells (HMEC) were purchased from StemCell
Technologies. H1299-κB-Luc and RCC45-p53-Luc cells were described (13) . κB-Luc and p53 reporter activity in these cells were confirmed by treatment with specific inducers (TNF and Curaxin-137 respectively). No additional authentication was done. Cells were grown in DMEM with 10% fetal bovine serum (Hyclone) and other standard supplements. HMEC cell medium was purchased from StemCell Technologies.
Ex-vivo cell culture
Tumor free mammary glands or necrosis-free mammary tumors were isolated from deeply anesthetized mice under sterile conditions, washed in PBS, minced with scissors and then incubated in 0.I % Type III Collagenase in complete culture medium (DMEM supplemented with 100 U/ml penicillin, 100 pg/ml streptomycin, 2 mM glutamine, 10 mM HEPES, 0.075% BSA, 10 ng/ml cholera toxin, 0.5 pg/ml hydrocortisone, 5 pg/ml insulin, and 5 ng/ml EGF) overnight at 37 o C on a shaking platform. After incubation, the cell suspension was centrifuged at 40Xg for 1 min. The pellet was washed once with PBS using the same centrifugation conditions. The final pellet was resuspended in complete culture medium and plated into plastic plates. The resulting "organoid" culture was used for an experiment within one week without additional replating.
Western blotting and immunofluorescent staining were performed using standard procedures. Antibodies used in the study are described in the Supplementary Materials.
Immunohistochemistry
Paraffin sections were cut at 5µm, placed on charged slides, and dried at 60°C for one hour. Slides were cooled to RT, deparaffinized in three changes of xylene, and rehydrated using graded alcohols. Endogenous peroxidase was quenched with aqueous 3% H 2 O 2. For antigen retrieval, slides were heated in a microwave for 20 m in citrate buffer (pH 6.0), cooled for 15 min and washed in 0.1%PBS/Tween20 solution. Slides were then loaded onto a Dako Autostainer and blocked for 5 m with serum-free protein block (Dako). After blocking, the slides were incubated with 0.2 µg/ml goat anti-mouse SSRP1 polyclonal antibody (Santa Cruz, sc-5909) for 1 h. An isotype-matched control antibody (0.2 µg/ml goat IgG) was used on a duplicate slide in place of the primary antibody as a negative control. After washing, slides were incubated with biotinylated donkey anti-goat IgG (Jackson ImmunoResearch Laboratories, Inc.) , followed by staining with the Elite ABC Kit (Vectastain), and DAB chromagen (Dako). Finally, stained slides were counterstained with Hematoxylin, dehydrated, cleared and coverslipped. All slides were scanned using Aperio scanscope (Aperio Technologies, Inc). Images were made using Image scope software (Aperio Technologies, Inc).
Microarray-based gene expression profiling
Total RNA was isolated from frozen tissue samples using TRIZOL reagent 
Safety of chronic administration of Curaxin-137 at MTD and ½ MTD in drinking water
Groups of 5 male MMTV-neu mice (4 weeks of age) were given either plain water or solutions of Curaxin-137 (at MTD or ½ MTD) in water ad libitum for 10 weeks. Mice were weighed once a week. After 10 weeks. mice were deeply anesthetized and blood was collected by cardiac puncture for plasma isolation. Major organs were collected for histopathological analysis, RNA isolation and measurement of Curaxin-137 concentration.
Cancer prevention study
Virgin female MMTV-neu mice (19-27 per group) were given either plain water or Curaxin-137 in water ad libitum. Curaxin-treated groups were given either 0.1 mg/ml Curaxin-137 starting at 4 weeks of age or 0.2 mg/ml Curaxin-137 starting at 10 weeks of age). Animals were monitored daily for signs of abnormalities and tumor appearance. They were weighed once a week for the first 24 weeks and then once a month. Animals that developed at least one visible tumor were transferred to drug-free water and kept until their cumulative tumor volume 
Curaxin-137-targeted factors, FACT, p53 and NF-κB, are frequently deregulated in mammary tumors of MMTV-neu mice
We next examined whether major factor known to be affected by in tumor cells, chromatin remodeling complex FACT, is involved in mammary carcinogenesis. We observed elevated expression of FACT in several human breast cancer cell lines comparing with normal primary and immortalized mammary epithelial cells ( Fig.2A) . We also noticed that while in tumor free mammary gland tissue of MMTV-neu animals SSRP1 and SPT16 were very low, in tumors isolated from the same animals levels of both subunits were elevated (Fig.2B) . Both SSRP1 and SPT16 protein levels were variable but in all cases higher than in tumor free tissue. To identify the stage of tumor formation at which 
abnormal mammary lesions of all stages from MMTV-neu mice (Fig.2C) . These data suggest that FACT levels are elevated early in the process of mammary epithelia transformation in MMTV-neu animals. As shown in Figure 3B , Curaxin-137 treatment resulted in disappearance of both FACT subunits, SSRP1 and SPT16, from soluble protein extracts of mammary tumor cells, while little or no SSRP1 or SPT16 protein was detected in tumor free mammary gland extracts (Fig.2B) (Fig. 3C) . Importantly, Curaxin-137 treatment led to significant nuclear relocalization of p65 without any additional stimulus, which is consistent with the previously defined specific mechanism of NF-κB inhibition by Curaxin-137 (Fig.3D ). Inflammation and activation of the NF-κB pathway through overexpression of p65 subunit was also shown to promote tumorigenesis in this model (11), (9) . Therefore Curaxin-137 induced inhibition of NF-κB may have protective effect at early stages of tumor transformation. showed that p53 levels were increased in a dose-dependent manner 6 hours after Curaxin-137 treatment of cells from a tumor-free mammary gland and mammary tumor with low basal level of p53 (Fig. 3E) . Several other tumors assessed showed high basal p53 levels and no induction in response to Curaxin-137 treatment, likely due to p53-stabilizing mutations (Fig. 3E) . We observed the similar result in tumors of mice treated with Curaxin-137 (Fig.3A) . These data confirmed the known fact that a high proportion of mammary tumors in this model have p53 pathway inactivated by p53 mutations (10) . The roles of p53 in mammary carcinogenesis in general and in this particular model have been wellstudied (10, 12) . It was shown that Her2 overexpression induces senescence in normal mammary cells and that this phenotype is overcome by inactivation of p53 (14) . Reported high incidence (37%) of p53 mutations in tumors developed in MMTV-neu mice (12) suggests that p53 activity interferes with tumor development and p53-inducing Curaxins treatment at pre-cancerous stage may enforce anti-cancer protective activity of p53.
These data, together with those described in the previous section, demonstrate that Curaxin-137 has desirable effects on multiple pathways 
Curaxin-137 can be administered to mice chronically with drinking water
Curaxin -137 is orally available and soluble in water (1). To establish a regimen of chronic administration for a cancer prevention study, we tested whether mice could be given the compound in their drinking water. MMTV-neu mice did not refuse drinking solutions of 0.1 or 0.2 mg/ml Curaxin-137, consuming the same volume of liquid in a given period of time as mice exposed to plain water (Fig.4A) . However, less liquid was consumed for more concentrated solutions of Curaxin-137 (data not shown). Conversion of the amount of solution consumed by mice into the actual dose of the drug indicated an average daily dose of Curaxin-137 of 13.8+/-2.2 mg/kg for the 0.1 mg/ml solution group as and 28.5+/-2.5 mg/kg for the 0.2 mg/ml group (Fig.4B) . MMTVneu mice given solutions of Curaxin-137 at these dose levels in place of regular drinking water between 4 and 14 weeks of age showed no difference in weight gain as compared to control animals given plain water (Fig.4C ). In addition, there were no observed differences between the mice in the Curaxin-137 treated and control groups during this period, except that one mouse had a hunched appearance for 2 days without any other changes in behavior or weight. No morphological differences were found between the study groups upon histopathological examination of internal parenchymal organs at the end of the observation period (10 weeks) (Supplementary Figure S1) . Moreover, what demonstrates that there is very little difference between Curaxin-treated and control animals (Fig. 4E) . These data indicate that chronic administration of Curaxin-137 does not cause any apparent systemic toxicity.
Since concentration of Curaxin-137 in drinking water higher than 0.2 mg/kg impeded liquid consumption by mice, this dose (0.2 mg/ml Curaxin-137 in drinking water; equivalent t to 28.5 mg/kg/day) was defined as the MTD for this administration regimen. This dose was very close to the previously established repetitive MTD for administration to mice by oral gavage (30 mg/kg). Table 1 ).
Importantly of Curaxin-137 at concentrations exceeding the LC50% for most tumor cells in vitro (0.2-0.6μM) did not cause any pathological changes in spleen or other organs analyzed (Supplementary Fig. S1 ). Therefore, we concluded that chronic administration of Curaxin-137 was safe enough to be tested as a tumor preventive regimen. (Fig. 4D ).
In the control group as well as the 0.1 mg/ml Curaxin-137-treated group, mammary tumors started being detected at 23-25 weeks of age (Fig. 5B) . In contrast, tumor appearance was delayed until 40 weeks of age in the 0.2 mg/ml Curaxin-137-treated group. Despite the fact that the kinetics of initial tumor appearance in the low dose Curaxin-treated group was similar to that in the control group, both the low and high dose Curaxin-treated groups were statistically different from the control group based on the comparison of KaplanMeyers curves of tumor-free survival using Log-rank test (Fig.5B) .
The median duration of tumor-free survival was 44 weeks in the control group and 57 and 78 weeks in the low and high dose Curaxin-treated groups, respectively (Fig. 5B ). There were minimal difference in the size of tumors between groups (Fig.5C ) and no difference in the life-span of tumor-bearing animals ( Fig.5D ) what most probably resulted from the regimen of administration used when Curaxin-137 administration was stopped after tumor appearance.
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Overall survival of animals treated with Curaxin-137 was longer than control animals in both treatment groups (Fig.5A) . Some animals in both Curaxin treated groups were still tumor-free at >18 months of age, while no control animals lived longer than 13 months (Fig. 5B and Supplementary Table 2 ). Besides in house pathological evaluation (Supplementary Fig.S1 ), the oldest surviving animals from each group were subjected to blind histopathological evaluation by phenotyping facility of University of Missouri (Supplementary Table 2 ). The oldest Curaxin-137-treated animals did not have any abnormalities that were different from those seen in the oldest surviving control mice (Supplementary Table 2 ).
This provides additional support for the general non-toxicity and safety of systemic Curaxin administration.
Curaxin-137 slows the progression of mammary tumors
We performed histological analyses on mammary glands with tumors isolated from mice in the three study group described in the preceding section when the cumulative tumor size per mouse was close to 2000mm 3 . Importantly this approach allowed analysis of tumors which were grown approximately the same time, therefore potential differences in their histology cannot be explained by the differences in tumor appearance. Tumors were excised and the morphology of each tumor was assessed on H&E stained sections. Tumors were graded according to the recommendations of ref. (15) as "undifferentiated" when the tumor mass was >90% solid cell mass with no traces of cells forming glandular or tubular structures (Fig. 6A) , "high grade" when >50% of the tumor mass was comprised of poorly organized, but recognizable glandular-like structures ( 
6B) or thick tubular structures (Fig. 6C) ; "glandular" when 100% of the tumor mass resembled glandular or tubular structures (Fig. 6D ) and "carcinoma in situ" when the tumor mass consists primarily of hyperplasic mammary epithelial structures ( Fig. 6E and F) . Analysis of the proportion of tumors of each type in each study group (control, 0.1 mg/ml or 0.2 mg/ml Curaxin-137-treated) demonstrated that more than half of the tumors in the control group had undifferentiated phenotypes and only minor proportions of the tumors were classified as more differentiated subtypes. In contrast, in both Curaxin-treated groups, most of tumors were more differentiated subtypes (Fig. 6G ). Since loss of differentiation is usually associated with tumor progression, the prevalence of more differentiated tumors in Curaxin-137 treated groups of mice suggests that chronic administration of the drug slowed tumor progression in the MMTV-neu breast cancer model.
Conclusions
The results of this study show that Curaxin-137 has anti-tumor efficacy when administered to tumor-prone MMTV-neu female mice in a preventive regimen.
The protective effect of Curaxin-137 was evidenced by reduced tumor incidence, 
